Dr. Younes on Brentuximab Plus AVD vs ABVD in Classical Hodgkin Lymphoma

Anas Younes, MD
Published Online: Thursday, Aug 28, 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the ongoing Echelon-1 study in classical Hodgkin lymphoma.

The current standard of care for patients with classical Hodgkin lymphoma is ABVD. A phase I trial that combined AVD with brentuximab vedotin showed promising safety and efficacy results.

The Echelon-1 study is a large, randomized trial aiming to compare ABVD with AVD plus brentuximab. The primary endpoint of the trial is modified progression-free survival: death, progression, receipt of chemotherapy or radiotherapy by patients not in complete response after completing front-line therapy.

Results of this trial could change practice, Younes says.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the ongoing Echelon-1 study in classical Hodgkin lymphoma.

The current standard of care for patients with classical Hodgkin lymphoma is ABVD. A phase I trial that combined AVD with brentuximab vedotin showed promising safety and efficacy results.

The Echelon-1 study is a large, randomized trial aiming to compare ABVD with AVD plus brentuximab. The primary endpoint of the trial is modified progression-free survival: death, progression, receipt of chemotherapy or radiotherapy by patients not in complete response after completing front-line therapy.

Results of this trial could change practice, Younes says.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Adverse Events with Targeted Therapies and ImmunotherapiesApr 30, 20171.0
Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference®May 18, 20172.0
Publication Bottom Border
Border Publication